Mesoblast Ltd Files 6-K with SEC
Ticker: MEOBF · Form: 6-K · Filed: Feb 14, 2025 · CIK: 1345099
| Field | Detail |
|---|---|
| Company | Mesoblast LTD (MEOBF) |
| Form Type | 6-K |
| Filed Date | Feb 14, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, regulatory-update
TL;DR
MESO files 6-K, attaching ASX announcement. Keep an eye out.
AI Summary
On February 14, 2025, Mesoblast Limited filed a Form 6-K with the SEC, attaching a new release announcement made to the Australian Securities Exchange. The filing incorporates this announcement by reference as Exhibit 99.1. Mesoblast Limited is a biotechnology company incorporated in Australia.
Why It Matters
This filing indicates Mesoblast Limited is providing updated information to the SEC, which could include significant business developments or regulatory updates relevant to investors.
Risk Assessment
Risk Level: low — This is a routine filing to incorporate an existing announcement, not indicating new material risks.
Key Players & Entities
- MESOBLAST LTD (company) — Registrant
- Silviu Itescu (person) — Chief Executive Officer and Executive Director
- February 14, 2025 (date) — Filing date
- 001-37626 (other) — SEC File Number
FAQ
What is the purpose of this Form 6-K filing?
The purpose of this Form 6-K filing is to report information that Mesoblast Limited has made or will make public, file or submit to any stock exchange on which it has securities listed, or distribute or publish to its security holders, and is otherwise required to file with the SEC. Specifically, it incorporates by reference a new release announcement filed with the Australian Securities Exchange.
When was this Form 6-K filed?
This Form 6-K was filed on February 14, 2025.
What is attached as Exhibit 99.1?
Exhibit 99.1 is a new release announcement that Mesoblast Limited filed with the Australian Securities Exchange.
Who is the Chief Executive Officer and Executive Director of Mesoblast Limited?
Silviu Itescu is the Chief Executive Officer and Executive Director of Mesoblast Limited.
Under which SEC Act is this report filed?
This report is filed under the Securities Exchange Act of 1934.
Filing Stats: 212 words · 1 min read · ~1 pages · Grade level 17.3 · Accepted 2025-02-13 19:30:34
Filing Documents
- a2025-02x15ryoncilattandem.htm (6-K) — 20KB
- exhibit991.htm (EX-99.1) — 9KB
- exhibit991001.jpg (GRAPHIC) — 225KB
- exhibit991002.jpg (GRAPHIC) — 290KB
- exhibit991003.jpg (GRAPHIC) — 46KB
- 0001345099-25-000008.txt ( ) — 803KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly organized. Mesoblast Limited s Paul Hughes Paul Hughes Company Secretary Dated February 15, 2025 INDEX TO EXHIBITS Item 99.1 Press release of Mesoblast Ltd, dated February 14, 2025.